The ADepT-PD trial (nortriptyline)

This trial is recruiting 408 people in 30 centres across the UK. Funded by the NIHR with support from Cure Parkinson’s, the trial lead is Professor Anette Schrag, the Royal Free Hospital, London. ADEPT-PD Antidepressants Trial in Parkinson’s Disease (ADepT-PD): A randomised placebo-controlled trial on…


The AND-PD Trial

This study (ANxiety with or without depressive features in Parkinson’s Disease ‘AND-PD’) is an observational and imaging study where people at different stages of Parkinson’s will be assessed and followed for one year. This study, led by Professor Anette Schrag, is looking to recruit around…


The AZA-PD Trial (azathioprine)

Dr Williams-Gray’s team at the University of Cambridge’s Centre for Parkinson-Plus are conducting a clinical trial of azathioprine (AZA-PD), a medication already used to treat inflammation by dampening down the immune system’s response, with the aim of slowing brain cell damage and slowing the progression of Parkinson’s….


The Bydureon (exenatide) phase 3 trial

Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon (a diabetes drug) phase 3 trial which has begun recruiting from six sites in the UK. This phase 3 efficacy trial in a larger cohort is the next stage in a programme of…


The PROSEEK trial – vodobatinib

Sun Pharma Advanced Research Company (SPARC) is conducting a Phase ll clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor vodobatinib (previously known as KO706) in people with early Parkinson’s.